Intersect ENT Reports Third Quarter 2015 Results

Go back to Intersect ENT Reports Third Quarter 2015 Results

Intersect ENT (XENT) Reports Slight Revenue Miss; Piper Jaffray Cuts Price Target to $23

November 5, 2015 10:00 AM EST

Piper Jaffray maintained an Overweight rating on Intersect ENT (NASDAQ: XENT), and cut the price target to $23.00 (from $30.00), following the company's 3Q earnings report and conference call. XENT reports revenues up 56%, slightly missing consensus of 60%.

Analyst Thomas Gunderson commented, "A slight... More